Healthcare Industry News: Mylan Laboratories
News Release - February 6, 2006
Mylan Announces FDA Approval for Cyclobenzaprine Hydrochloride Tablets USP, 5 mgPITTSBURGH, Feb. 6 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Cyclobenzaprine Hydrochloride Tablets USP, 5 mg. Cyclobenzaprine Tablets are the AB-rated generic equivalent of McNeil's FlexerilŽ Tablets. U.S. sales for the 5 mg strength of FlexerilŽ were approximately $93 million for the 12-month period ending June 30, 2005, according to IMS Health.
This product will begin shipping immediately.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.
For more information about Mylan, visit http://www.mylan.com.
Source: Mylan Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.